Date: 2011-03-21
Type of information: Collaboration agreement
Compound: rabbit monoclonal antibodies to be used in diagnosing cancer and in developing predictive assays for cancer patients (companion diagnostics)
Company: Dako (Denmark) Epitomics (USA)
Therapeutic area: CancerOncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: Dako and Epitomics have entered into a collaboration which will allow the companies to unite competencies to provide the Anatomic Pathology market with state-of-the-art antibodies. This strategic alliance will combine the competencies of Dako and Epitomics to establish the optimal portfolio of very high quality rabbit monoclonal antibodies to be used in diagnosing cancer and in developing companion diagnostics. Besides the development and launch of new state-of-the-art monoclonal antibodies the strategic alliance between Dako and Epitomics also includes a technology transfer from Epitomic's to Dako's facilities.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
